Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc. has demonstrated strong financial growth, with Cell Processing revenue reaching $25.3 million, up 33% year-over-year, and evo and Thaw revenue increasing to $2.8 million, up 15% year-over-year. The company has also raised its 2025 revenue guidance to between $100 to $103 million, reflecting a projected 22-25% growth, supported by robust expectations for Cell Processing and evo and Thaw revenue. Additionally, management anticipates a reduction in net loss and continued improvement in adjusted EBITDA margins, indicating a positive trajectory for the company's financial health.

Bears say

BioLife Solutions Inc faces several fundamental risks that contribute to a negative outlook, including lower-than-projected growth of products and services, difficulty in securing additional customers, and fluctuations in sales due to foreign exchange rates. The company reported a significant net loss of $15.8 million, primarily influenced by a $15.5 million in-process research and development expense associated with the PanTHERA transaction, which exceeded previous estimates. Furthermore, revenue guidance for FY2025 was adjusted downwards, reflecting a decrease of approximately $8 million and projecting only 27-29% year-over-year growth, raising concerns about the sustainability of its Cell Processing revenue stream.

BioLife Solutions (BLFS) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Buy based on their latest research and market trends.

According to 2 analysts, BioLife Solutions (BLFS) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.